Imaging intelligence company VIDA Diagnostics has launched its updated artificial intelligence (AI)-enabled Intelligence platform, VIDA Intelligence Portal 2.0, that drives clinical trial imaging operation efficiencies.
The platform has been launched to accelerate the onboarding of clinical trial sites.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It increases efficiencies in imaging operations by optimising image data collection, staff training, and data quality, curation, and management.
The company stated that the VIDA Intelligence Portal 2.0’s new digital onboarding features simplify the participants enrolment process for clinical trial sites.
Since the release, the global network of sites that are equipped with the VIDA Intelligence Portal has expanded to over 1,000 in less than a year.
Now, imaging centres and hospitals are also collaborating with VIDA Diagnostics to take part in clinical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLast month, many other imaging centre groups in Europe and the US also signed deals with VIDA Diagnostics.
VIDA Diagnostics chief technology officer Todd Johnson said: “We are thrilled to see sponsors and trial sites across the globe embracing VIDA Intelligence Portal.
“By empowering new sites to participate in imaging-based clinical trials, we are proud to be extending patient access to novel therapy opportunities.
“The enhancements to VIDA Intelligence Portal make it easier for sites to become fully certified and operational, and to quickly enrol in trials with full confidence in the quality of their image acquisition, staff training, and readiness.”
Last month, RAYUS Radiology, an advanced diagnostic and interventional radiology provider, collaborated with VIDA Diagnostics for decentralised clinical trials.
This collaboration was aimed at addressing the challenges for imaging sites and enabling them to participate in imaging-based clinical trials.
